Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Abstract Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient eliminat...
Main Authors: | Zhiwen Fu, Shijun Li, Sifei Han, Chen Shi, Yu Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-03-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-022-00947-7 |
Similar Items
-
Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates
by: Zhiwen Fu, et al.
Published: (2023-10-01) -
Drug conjugates for targeting regulatory T cells in the tumor microenvironment: guided missiles for cancer treatment
by: Juwon Yang, et al.
Published: (2023-09-01) -
Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
by: Md Abdus Subhan, et al.
Published: (2023-04-01) -
Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
by: Devesh Aggarwal, et al.
Published: (2023-08-01) -
Corrigendum to “Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis” [EClinicalMedicine 55 (2022) 101795]
by: Zhiwen Fu, et al.
Published: (2023-04-01)